CARMELINA is a randomized, double-blind, placebo-controlled clinical trial with the aim to examine the effect of linagliptin,
an DPP-4 inhibitor, in comparison with placebo, on incidence of cardiovascular and renal outcomes in patients
with type 2 diabetes mellitus with high cardio-renal risk on top of standard care. The primary composite outcome
was death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke. The key secondary
endpoint was the time to first occurrence of kidney death, sustained end-stage kidney disease or sustained decrease
of ≥40% in eGFR. This study fulfils requirements of FDA and EMA for assessement of cardiovascular safety,
but is also studies renal benefit of linagliptin, Results of this study will be first time presented at the 54. annual
meeting in Berlin in September 2018.